The concept that life-threateomg ventricular tachyarrhythmiss could be terminated in closed chest subjects by mcan$ ofinternally delivered electrical countershocks. and that this maneuver could be performed automatically by an electronic device pemtanently implanted in high risk pattent~ to protect them from arrhythmic death, goes back to the late 1960s (12). Initially. the idea was not well received by critics (3) and hardly caotured the lmaeination of either clinicians or engineers: In b.
its acronym AICD. Experience indicates that the device oerforms I~C deslgned funcoons ~adsfactorily. that the risks wrociated with its USC are moderate and frequentty avoidable and. most importantly, fbat its impact on the wrvivat of [be implaniees 1s dramatic indeed. Although the sudden death monabty in the types of patients operated on ranges between 27 and 66% at I year (t t-14) in historical control patients. it has been consisantly found to be <2% in those who received the AICD l&21).
The Irnptirations. If the history of artificial cardiac pacing is any guide. implantation of the automatic cardioverterdefibrillator will soon be transformed ioio a simple pad relatively noninvasive intervention. With further anticipated impmvements in defibrillating catheter technology, it is not unreasonable to expect that nonthoracotomy approaches wdl become routine implantation techniques. The clinical relevance of wch a development cannot be underestimated at a time when the AICD is being recognized as an essential modality in the management of survivors of arrhythmic cardiac arrest and of other patients suffering from malignant ventricular tachyarrhythmias.
